TGFB3 and diabetes mellitus: The biocompatibility and therapeutic potential of the BP-QS/TGF-β3 hydrogel were evaluated through in vitro assays (CCK-8, apoptosis, hemolysis) and in a streptozotocin-induced diabetic mouse model, respectively, against controls including PBS, BP-QS (blank hydrogel), and free TGF-β3 solution.